Actively Recruiting
Phase 12 Study of ZG006 Given by IV to Treat Adults With Small Cell Lung Cancer or Neuroendocrine Carcinoma Who Have No Standard Treatment Options
Led by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Updated on 2026-01-05
54
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ZG006 in a Phase 12 clinical trial for adults aged 18 to 75 with small cell lung cancer or neuroendocrine carcinoma who either have no standard treatment options or cannot tolerate standard treatments. This multi-center, open-label study aims to understand the safety, tolerability, pharmacokinetics, and effects of ZG006 in this patient population. Participants will receive ZG006 through intravenous infusion. The study includes a dose-escalation phase using accelerated titration for lower doses and a conventional dose escalation method for higher doses to find the maximum tolerated dose and recommended dose for Phase 2. After dose exploration, participants will receive the identified optimal dose during the dose expansion phase. During the trial, participants will be closely monitored for dose-limiting toxicities within 28 days after the first dose, as well as adverse events, laboratory results, and changes in ECGs for up to two years. Researchers will also assess treatment response, including tumor control and drug concentration levels in the blood. The total study duration may last up to two years, including safety and efficacy follow-up.
CONDITIONS
Brief Title
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Research Team
H
Hewen Yin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here